![](https://endpts.com/wp-content/uploads/2019/07/Vas-Narasimhan-endpts-tile-AP-Images.jpg)
Vas Narasimhan (Credit: AP)
Novartis nabs FDA approval for hyped Eylea rival
As Regeneron’s Eylea stares down potential slow-death-by-generics, Novartis has nabbed a widely expected FDA approval for its own wet macular degeneration injection, Beovu (brolucizumab). …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.